Prajwal Dhakal1, Christopher S Wichman2, Bunny Pozehl3, Meaghann Weaver4,5, Alfred L Fisher6, Julie Vose7,8, R Gregory Bociek7,8, Vijaya R Bhatt7,8. 1. Department of Internal Medicine, Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa Health Care, Iowa City, IA 52242, USA. 2. Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE 68198,USA. 3. College of Nursing - Omaha Division, University of Nebraska Medical Center, Omaha, NE 68198, USA. 4. Division of Pediatric Palliative Care, Children's Hospital & Medical Center, Omaha, NE 68114, USA. 5. Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA. 6. Division of Geriatrics, Gerontology and Palliative Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA. 7. Department of Internal Medicine, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA. 8. Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA.
Abstract
Background: We used the Therapy Preference Scale, a 30-item questionnaire, to determine cancer treatment preferences of adults with cancer. Methods: We used Wilcoxon's rank sum test and Fisher's exact test to compare the preferences of younger (<60 years) versus older adults (≥60 years). Results: While 56% of patients would accept treatment offering increased life expectancy at an expense of short-term side effects, 75% preferred maintenance of cognition, functional ability and quality of life to quantity of days. Oral instead of intravenous treatment (p = 0.003), shorter hospital stay (p = 0.03), preservation of cognitive function (p = 0.01) and avoidance of pain (p = 0.02) were more important to older patients compared with younger patients. Conclusion: Many patients prioritized maintenance of cognition, functional ability and quality of life; older patients valued oral treatment, shorter hospital stay, preservation of cognitive function and avoidance of pain.
Background: We used the Therapy Preference Scale, a 30-item questionnaire, to determine cancer treatment preferences of adults with cancer. Methods: We used Wilcoxon's rank sum test and Fisher's exact test to compare the preferences of younger (<60 years) versus older adults (≥60 years). Results: While 56% of patients would accept treatment offering increased life expectancy at an expense of short-term side effects, 75% preferred maintenance of cognition, functional ability and quality of life to quantity of days. Oral instead of intravenous treatment (p = 0.003), shorter hospital stay (p = 0.03), preservation of cognitive function (p = 0.01) and avoidance of pain (p = 0.02) were more important to older patients compared with younger patients. Conclusion: Many patients prioritized maintenance of cognition, functional ability and quality of life; older patients valued oral treatment, shorter hospital stay, preservation of cognitive function and avoidance of pain.
Entities:
Keywords:
cancer; cognition; life expectancy; patients; preferences; quality of life; questionnaire; therapy; treatment
Authors: I Kuchuk; N Bouganim; K Beusterien; J Grinspan; L Vandermeer; S Gertler; S F Dent; X Song; R Segal; S Mazzarello; F Crawley; G Dranitsaris; M Clemons Journal: Breast Cancer Res Treat Date: 2013-10-16 Impact factor: 4.872
Authors: S Yousuf Zafar; Jeffrey M Peppercorn; Deborah Schrag; Donald H Taylor; Amy M Goetzinger; Xiaoyin Zhong; Amy P Abernethy Journal: Oncologist Date: 2013-02-26
Authors: Stacie B Dusetzina; Aaron N Winn; Gregory A Abel; Haiden A Huskamp; Nancy L Keating Journal: J Clin Oncol Date: 2013-12-23 Impact factor: 44.544
Authors: Pang-Hsiang Liu; Mary Beth Landrum; Jane C Weeks; Haiden A Huskamp; Katherine L Kahn; Yulei He; Jennifer W Mack; Nancy L Keating Journal: J Palliat Med Date: 2014-04-17 Impact factor: 2.947
Authors: Victoria C Hamelinck; Esther Bastiaannet; Arwen H Pieterse; Nienke A de Glas; Johanneke E A Portielje; Jos W S Merkus; Irma D M den Hoed; Cornelis J H van de Velde; Gerrit-Jan Liefers; Anne M Stiggelbout Journal: Clin Breast Cancer Date: 2016-04-21 Impact factor: 3.225
Authors: Petronella A L Nelleke Seghers; Anke Wiersma; Suzanne Festen; Mariken E Stegmann; Pierre Soubeyran; Siri Rostoft; Shane O'Hanlon; Johanneke E A Portielje; Marije E Hamaker Journal: Cancers (Basel) Date: 2022-02-23 Impact factor: 6.639
Authors: Petronella A L Nelleke Seghers; Jolina A Kregting; Lieke H van Huis-Tanja; Pierre Soubeyran; Shane O'Hanlon; Siri Rostoft; Marije E Hamaker; Johanneke E A Portielje Journal: Cancers (Basel) Date: 2022-02-22 Impact factor: 6.639